Viral Hepatitis in Infants and Children

Viral Hepatitis
in
Infants and Children
Ricardo A. Caicedo, M.D.
Pediatric Gastroenterology and Nutrition
Wake Forest University Baptist Medical Center
Learning Objectives
• Recognize the clinical manifestations of
viral hepatitis in the pediatric population
• Understand the natural history of
hepatotropic viral infections in children
• Become familiar with the diagnosis and
management of pediatric viral hepatitis
Topics
•
•
•
•
Hepatotropic Viruses
Acute vs. Fulminant vs. Chronic
Hepatitis A virus
Hepatitis B virus
– Diagnosis
– Natural history
– Immunoprophylaxis/management
• Hepatitis C virus
– Diagnosis
– Natural history
– Management
• Other viral agents
www.microscopyu.com
Hepatotropic Viruses
PRIMARY
–
–
–
–
Hepatitis A Virus (HAV)
Hepatitis B Virus (HBV)
Hepatitis C Virus (HCV)
Hepatitis D Virus (HDV)
• Requires HBV co-infection
– Hepatitis E Virus (HEV)
– Hepatitis F Virus
(controversial)
– Hepatitis G Virus
(pathogen?)
SYSTEMIC
–
–
–
–
–
–
–
–
–
Cytomegalovirus (CMV)
Epstein-Barr Virus (EBV)
HIV
Adenovirus
Parvovirus B19
Rubella
Coxsackievirus B
Enteroviruses
Human Herpes Viruses
• Herpes Simplex Virus (HSV)
• HHV-6
• Varicella Zoster Virus (VZV)
Acute Viral Hepatitis
• Acute hepatocellular injury/inflammation
– Reflected by elevated transaminases (AST or SGOT,
ALT or SGPT)
– Clinical manifestations often include fever, malaise,
jaundice, RUQ pain, nausea/vomiting
• Typically self-limited and of short duration
– Contrast with: chronic, fulminant
• Causative agents
– HAV (50% of cases in U.S.), HEV
– CMV, EBV, VZV
Fulminant Hepatitis
• Acute, massive hepatocellular necrosis
• Impaired synthetic, excretory, and detoxifying
functions of the liver
– Cholestasis, ascites, coagulopathy, encephalopathy,
multi-system failure
– Initially very elevated transaminases
» Falling transaminases and rising bilirubin ominous
– Hyperammonemia, hypoalbuminemia, prolonged PT,
hypoglycemia
• Viral agents (50% of cases)
– Most cases of fulminant hepatic failure are caused by
unidentified agent, presumably viral
• HAV, HBV+/-HDV, HCV, HEV
• HSV, enteroviruses, EBV, CMV, HHV-6, VZV
Chronic Hepatitis
• Prolonged necroinflammatory process
– Elevated transaminases for > 4-6 months
– Insidious clinical manifestations
• Can include cholestasis (jaundice, pruritus),
ascites, hypoalbuminemia, coagulopathy,
encephalopathy
• Can progress to fibrosis and then cirrhosis
• Viral agents: HBV (+/- HDV), HCV
• Other causes include autoimmune, metabolic
disorders (Wilson’s, CF, alpha-1 antitrypsin deficiency),
drug/toxin-mediated, idiopathic
Chronic Viral Hepatitis
Risk Factors
Hochman J, Balistreri WF. Pediatr Rev. 2003; 24:399-410.
Hepatitis A Virus
• Causes 33% of acute viral hepatitis in U.S.
– NOT a cause of chronic hepatitis
– rarely causes fulminant hepatitis (< 1% cases)
• Can trigger autoimmune hepatitis in predisposed individuals
• Epidemiologic factors
–
–
–
–
Fecal-oral transmission
Poor hygiene
High population density
Daycare centers and minor epidemics
HAV
• Acute, self-limited illness
– Fever, malaise, anorexia, vomiting, nausea, abdominal pain,
diarrhea
– Elevated AST/ALT
– Jaundice (conjugated hyperbilirubinemia) usually 1 wk after
onset of symptoms
– Duration
• Age < 6 y: typically, <2 wks
• Older children and adults can have prolonged course and often
have hepatomegaly
• Dx: serology
– Anti-HAV IgM
• Supportive care
HAV Course
Quiros-Tejeira RE. Up to Date v. 14.3, 2006.
HAV Vaccine
• Prevents morbidity and mortality associated with
HAV infection
– Incidence of HAV in U.S. has decreased by 75%
since vaccine introduced in 1997
• Because humans are the only known reservoir for HAV,
universal immunization strategies could hypothetically
eradicate HAV
• AAP Recommendation, 2006
– All children age 12-23 months should be immunized
• Extended safety data supports incorporation of HAV vaccine
into routine childhood immunization schedule
Recommended Standard Childhood
Immunization Schedule, 2006
www.cdc.gov/nip/recs/child-schedule.htm
Hepatitis B Virus
• Hepadnavirus
– Double-stranded DNA
• “A retrovirus in disguise”
– Multiple genotypes and serotypes
• Replication factory
– Significant mutation rate
• Can “escape” serological detection and/or vaccine
• Triggers host immune attack on liver cells
– T-cell-mediated hepatocellular lysis
• Chronic infection results from ineffective immune response
HBV Epidemiology
• Worldwide
– Persons infected: 2 billion
– Persons with chronic HBV: 350 million
– Annual deaths: 1 million
• U.S.
– Chronic HBV: 1.25 million
– Annual deaths: 5000
HBV Transmission
• Sexual
– High risk: non-monogamous heterosexual and
all homosexual encounters
•
•
•
•
Vertical (maternal-fetal)
Intravenous drug use
Hemodialysis
Blood products
– Risk of acquiring HBV from blood transfusion:
< 1:60000
HBV Manifestations
• Incubation period: 45-160 d
• Prodromal “flu-like” illness
– Malaise, fatigue, anorexia, nausea, fever
• Jaundice
– Cholestasis
• Elevated AST/ALT
• Less common
– Fulminant hepatitis: coagulopathy, encephalopathy
• 1-5% of HBV cases
– Glomerulonephritis, arthritis
– Papular acrodermatitis (Giannotti-Crosti)
Papular acrodermatitis
Screening for HBV
• TESTS: HBsAg and anti-HBs
• Adolescents who engage in high-risk behaviors
– IV or intranasal drug abuse
– unprotected sex with an infected partner or > 1 partner
– Hx of STD
• All internationally adopted children
• Immigrants from high-prevalence areas
– Africa, SE Asia, the Middle East except Israel, the interior
Amazon River basin, Haiti/D.R.
• Children living in communities where HBV is endemic
• Household contacts of individuals with HBV infection
• Infants born to women with HBV infection
– If infant got hepatitis B immune globulin and hepatitis B vaccine
at birth, followed by two additional immunizations, test at 9-15 m
– Unimmunized should be tested as soon as identified
HBV Diagnosis
Hochman J, Balistreri WF. Pediatr Rev. 2003; 24: 399-410.
HBV Diagnosis
SEROLOGIC RESPONSES
Lok ASF. Up to Date v. 14.3, 2006.
HBV Serology
•
•
•
•
HBsAg: +
Anti-HBc: +
IgM anti-HBc: +
Anti-HBs: INTERPRETATION:
Acute HBV infection
•
•
•
•
HBsAg: +
Anti-HBc: +
IgM anti-HBc: Anti-HBs: INTERPRETATION:
Chronic HBV infection
HBV Serology
• HBsAg: • Anti-HBc: +
• Anti-HBs: +
INTERPRETATION:
Immunity due to
natural infection
• HBsAg: • Anti-HBc: • Anti-HBs: +
INTERPRETATION:
Immunity due to
HBV vaccination
HBV Course
Hochman J, Balistreri WF. Pediatr Rev. 2003; 24: 399-410.
HBV Sequelae
Risk of
Chronic HBV
95%
30%
5%
Occurs in 2050% by age 72
in absence of
prevention or tx
Hochman J, Balistreri WF. Pediatr Rev. 2003; 24: 399-410.
Evaluation of HBsAg+ Patients
•
•
•
•
•
•
•
•
AST/ALT, T/D bilirubin
PT/INR, albumin
HBV DNA
Anti-HBc, Anti-HBe, HBeAg
Serology for HAV, HCV, HDV
Test for HIV and other STDs
Test household and sexual contacts
If chronic
– Ultrasound
– Liver biopsy
– Alpha feto-protein (AFP)
Lin KW, Kirchner JT. Am Fam Physician 2004; 69:75-82.
Management
Pediatric Chronic HBV
• Prove chronic infection
• > 2 HBsAg+ samples 6 months apart
• OR anti-HBc+, IgM anti-HBc –
• Follow ALT q 6 months
• If > 1.5-2X normal, liver biopsy and consider treatment
• Yearly
• HBeAg and anti-HBe (look for seroconversion)
• Ultrasound and AFP
• Immunize
• HAV vaccine
• All household contacts
Jonas MM, NASPGHAN Postgraduate Course, 2005.
HBV Treatment
Lin KW, Kirchner JT. Am Fam Physician 2004; 69:75-82.
GOALS of TREATMENT
- Suppress HBV replication
- Seroconversion from eAg to e Ab
- Prevent long-term sequelae
• Interferon-alfa
• Lamivudine
• Adefovir
HBV Immunoprophylaxis
PASSIVE: HBIG
• In conjunction with
vaccine
• Perinatal exposure
• Occupational exposure
(needle stick)
• Household contact
exposed to blood
ACTIVE: HBV Vaccine
• AAP recommends
immunizing all newborns
• Started in 1991
• By end of 1990s, rate of
acute HBV in children
reduced by 75%
• Taiwan: vaccination program
reduced incidence of
HBsAg+, HCC, and
fulminant hepatitis
– No objective evidence linking
vaccine to multiple sclerosis
or autism
HBV Prophylaxis
• NEONATAL
• Routine screening of all pregnant women for HBsAg is now
mandatory
• HBsAg-negative mother: Infant vaccinated at birth; at 1-2 m;
at 6-18 m
• Infants born to mothers with unknown or known positive HBsAg
status: HB immune globulin (HBIG) plus the 1st dose HB vaccine
within 12 h of birth, 2nd at 1-2 m; 3rd at 6 m
• OTHER
– Post-exposure (occupational): for nonvaccinated individuals or
absence of documented response
– High risk groups
•
•
•
•
Healthcare workers
Chronic liver disease
Dialysis or chronic parenteral therapy recipients
High risk behaviors (IV drug use, unprotected sex)
Hepatitis C Virus
• Discovered 1989
• Post-transfusion “non-A, non-B hepatitis”
• RNA flavivirus
• Difficult to clear
– Genetic heterogeneity
• 9 known genotypes
• Rapid mutation rate
• Exists as mixture of closely related mutants (quasispecies) within an individual host
HCV Epidemiology
• Prevalence
• Adults: 2%
• Children: 0.2%, Adolescents: 0.4%
• Transmission
– Maternal-fetal
• Mother HCV+: 5% risk
• Mother co-infected with HIV: 15% risk
• All infants born to HCV-infected mothers should be tested for
anti-HCV Ab after 12 m of age
– Blood transfusion
– Screening blood products has reduced risk to <1:100,000
– Other risk factors
– High risk sexual behavior
– IV drug abuse
– Tattooing, body piercing
HCV Sequelae
Mild systemic
illness; usually
without
jaundice
C = Chronic; chronic infection develops in
most patients with HCV
HCV Diagnosis
Hochman J, Balistreri WF. Pediatr Rev. 2003; 24: 399-410.
HCV Management
• No immunoprophylaxis available
• Screen for and vaccinate vs. HAV & HBV
• Avoid hepatotoxins
• Acetaminophen, alcohol
• Follow-up at regular intervals
• Follow LFT
• AFP, ultrasound (screen for HCC)
• Treatment in selected patients
–
–
–
–
–
Prevent progression to cirrhosis
If HCV identified during acute stage - eradication
Pegylated-interferon (choice in adults)
PEG-IFN + ribavirin (multicenter pediatric trial)
Liver transplantation: indicated for cirrhosis or HCC
Viral Hepatitis
Consultation with Pediatric GI
Hochman J, Balistreri WF. Pediatr Rev. 2003; 24: 399-410.
Breastfeeding
• HBsAg+ mothers
– can breastfeed as long as neonate has
received HBIG and vaccine within 12 h of
birth
• HCV+ mother is not contraindication to
breastfeeding
– Data re: transmission in human milk is limited
CMV
• Usually acute self-limited hepatitis
–
–
–
–
–
Mononucleosis syndrome with fever
Typically anicteric
Transaminases peak at 200s at 2-3 wks
Dx: IgM, antigenemia, PCR
Rarely causes fulminant hepatitis
• Can treat with ganciclovir or foscarnet
– More severe cases
• Immunocompromised
• Chronic liver disease
EBV
• Classic infectious mononucleosis
syndrome
– Fever, sore throat, fatigue
– Cerv. lymphadenopathy, splenomegaly
• Liver insult secondary to infected T cells
– Mild anicteric hepatitis in most cases
• Dx = EBV serology, PCR
• Fulminant course (1:3000 cases)
– Severe hepatitis, bone marrow failure
North American Society for Pediatric Gastroenterology,
Hepatology and Nutrition
www.naspghan.org
www.cdhnf.org
www.hepb.org
www.aasld.org
Download
Related flashcards
Blood disorders

42 Cards

Blood donation

15 Cards

Myeloid neoplasia

12 Cards

Hematology

51 Cards

Create flashcards